Alzheimer's disease and the amyloid β protein: What is the role of amyloid?

Journal of Neurochemistry

Volumn 73, Issue 2, 1999, Pages 443-449

  Small, David H ^a   McLean, Catriona A ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID; AMYLOID BETA PROTEIN; PRESENILIN 1;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; HUMAN; MOUSE; NEUROFIBRILLARY TANGLE; NEUROTOXICITY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; SHORT SURVEY; TRANSGENIC MOUSE;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; AMYLOIDOSIS; HUMANS;

ANIMALIA; MUS MUSCULUS;

EID: 0032814135     PISSN: 00223042     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1471-4159.1999.0730443.x     Document Type: Short Survey

References (96)

1. Alzheimer A. (1907) Über eine eigenartige Erkrankung der Hirnrinde. Allg. Z. Psychiatr. Psychisch-gerichtli. Med. 64, 146-148.
2. Arriagada P. V., Growdon J. H., Hedley-Whyte E. T., and Hyman B. T. (1992) Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology 42, 631-639.
3. Bales K. R., Verina T., Dodel R. C., Du Y., Altstiel L., Bender M., Hyslop P., Johnstone E. M., Little S. P., Cummins D. J., Piccardo P., Ghetti B., and Paul S. M. (1997) Lack of apolipoprotein E dramatically reduces amyloid β-peptide deposition. Nat. Genet. 17, 263-264.
4. Behl C., Davis J. B., Lesley R., and Schubert D. (1994) Hydrogen peroxide mediates amyloid beta protein toxicity. Cell 77, 817-827.
5. Braak H. and Braak E. (1996) Development of Alzheimer-related neurofibrillary changes in the neocortex inversely recapitulates cortical myelogenesis. Acta Neuropathol. (Berl.) 92, 197-201.
6. Butterfield D. A., Hensley K., Harris M., Mattson M., and Carney J. (1994) β-Amyloid peptide free radical fragments initiate synaptosomal lipoperoxidation in a sequence-specific fashion: implications to Alzheimer's disease. Biochem. Biophys. Res. Commun. 200, 710-715.
7. Café C., Torri C., Bertorelli L., Angeretti N., Lucca E., Forloni G., and Marzatico F. (1996) Oxidative stress after acute and chronic application of β-amyloid fragment 25-35 in cortical cultures. Neurosci. Lett. 203, 61-65.
8. Cai X. D., Golde T. E., and Younkin S. G. (1993) Release of excess amyloid β protein from a mutant amyloid β protein precursor. Science 259, 514-516.
9. Calhoun M. E., Wiederhold K. H., Abramowski D., Phinney A. L., Probst A., Sturcher-Pierrat C., Staufenbiel M., Sommer B., and Jucker M. (1998) Neuron loss in APP transgenic mice. Nature 395, 755-756.
10. Chartier-Harlin M. C., Crawford F., Houlden H., Warren A., Hughes D., Fidani L., Goate A., Rossor M., Roques P., Hardy J., and Mullan M. (1991) Early-onset Alzheimer's disease caused by mutations at codon 717 of the β-amyloid precursor protein gene. Nature 353, 844-846.
11. Combs C. K., Johnson D. E., Cannady S. B., Lehman T. M., and Landreth G. E. (1999) Identification of microglial signal transduction pathways mediating a neurotoxic response to amyloidogenic fragments of β-amyloid and prion proteins. J. Neurosci. 19, 928-939.
12. Cordell B., Tischer E., and Higaki J. (1998) What inhibitors and mutant substrates reveal about gamma-secretase processing of β-APP. Neurobiol. Aging 19 (Suppl. 4), 223.
13. Crook R., Verkkoniemi A., Perez-Tur J., Mehta N., Baker M., Houlden H., Farrer M., Hutton M., Lincoln S., Hardy J., Gwinn K., Somer M., Paetau A., Kalimo H., Ylikoski R., Pöyhönen M., Kucera S., and Haltia M. (1998) A variant of Alzheimer's disease with spastic paraparesis and unusual plaques due to deletion of exon 9 of presenilin 1. Nat. Med. 4, 452-455.
14. Cummings B. J. and Cotman C. W. (1995) Image analysis of β-amyloid load in Alzheimer's disease and relation to dementia severity. Lancet 346, 1524-1528.
15. Davidson R. M., Shajenko L., and Donta T. S. (1994) Amyloid β-peptide (AβP) potentiates a nimodipine-sensitive L-type barium conductance in N1E-115 neuroblastoma cells. Brain Res. 643, 324-327.
16. Davis J. N. II and Chisholm J. C. (1997) The 'amyloid cascade hypothesis' of AD: decoy or real McCoy? Trends Neurosci. 20, 558-559.
17. de Silva H. A. R. and Patel A. J. (1997) Presenilins and early-onset familial Alzheimer's disease. Neuroreport 8, i-xii.
18. De Strooper B., Saftig P., Craessaerts K., Vanderstichele H., Guhde G., Annaert W., Vonfigura K., and Vanleuven F. (1998) Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein. Nature 391, 387-390.
19. Eckman C. B., Mehta N. D., Crook R., Perez-Tur J., Prihar G., Pfeiffer E., Graff-Radford N., Hinder P., Yager D., Zenk B., Refolo L. M., Prada C. M., Younkin S. G., Hutton M., and Hardy J. (1997) A new pathogenic mutation in the APP gene (I716V) increases the relative proportion of A beta 42(43). Hum. Mol. Genet. 6, 2087-2089.
20. Esch F. S., Keim P. S., Beattie E. C., Blacher R. W., Culwell A. R., Oltersdorf T., McClure D., and Ward P. J. (1990) Cleavage of amyloid β peptide during constitutive processing of its precursor. Science 248, 1122-1124.
21. Estus S., Golde T. E., Kunishita T., Blades D., Lowery D., Eisen M., Usiak M., Qu X., Tabira T., Greenberg B. D., and Younkin S. (1992) Potentially amyloidogenic, carboxyl-terminal derivatives of the amyloid protein precursor. Science 255, 726-728.
22. Frautschy S. A., Baird A., and Cole G. M. (1991) Effects of injected Alzheimer β-amyloid cores in rat brain. Proc. Natl. Acad. Sci. USA 88, 8362-8366.
23. Frautschy S. A., Yang F. S., Irrizarry M., Hyman B., Saido T. C., Hsiao K., and Cole G. M. (1998) Microglial response to amyloid plaques in APPSW transgenic mice. Am. J. Pathol. 152, 307-317.
24. Funato H., Yoshimura M., Kusui K., Tamaoka A., Ishikawa K., Ohkoshi N., Namekata K., Okeda R., and Ihara Y. (1998) Quantitation of amyloid β-protein (Aβ) in the cortex during aging and in Alzheimer's disease. Am. J. Pathol. 152, 1633-1640.
25. 2+ influx. J. Neurochem. 65, 1061-1068.
26. Games D., Adams D., Alessandrini R., Barbour R., Berthelette P., Blackwell C., Carr T., Clemens J., Donaldson T., Gillespie F., Guido T., Hagopian S., Johnson-Wood K., Khan K., Lee M., Leibowitz P., Lieberburg I., Little S., Masliah E., McConlogue L., Montoya-Zavala M., Mucke L., Paganini L., Penniman E., Power L., Schenk D., Seubert P., Snyder B., Soriano F., Tan H., Vitale J., Wadsworth S., Wolozin B., and Zhao J. (1995) Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein. Nature 373, 523-527.
27. Geula C., Wu C. K., Saroff D., Lorenzo A., Yuan M., and Yankner B. A. (1998) Aging renders the brain vulnerable to amyloid β-protein neurotoxicity. Nat. Med. 4, 827-831.
28. Glenner G. G. and Wong C. W. (1984) Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem. Biophys. Res. Commun. 120, 885-890.
29. Goate A., Chartier-Harlin M. C., Mullan M., Brown J., Crawford F., Fidani L., Giuffra L., Haynes A., Irving N., James L., Mant R., Newton P., Rooke K., Roques P., Talbot C., Pericak-Vance M., Roses A., Williamson R., Rossor M., Owen M., and Hardy J. (1991) Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature 349, 704-706.
30. Golde T. E., Estus S., Younkin L. H., Selkoe D. J., and Younkin S. G. (1992) Processing of the amyloid protein precursor to potentially amyloidogenic derivatives. Science 255, 728-730.
31. Haass C., Schlossmacher M. G., Hung A. Y., Vigo-Pelfrey C., Mellon A., Ostaszewski B. L., Lieberburg I., Koo E. H., Schenk D., Teplow D. B., and Selkoe D. J. (1992) Amyloid β-peptide is produced by cultured cells during normal metabolism. Nature 359, 322-325.
32. Haass C., Hung A. Y., Selkoe D. J., and Teplow D. B. (1994) Mutations associated with a locus for familial Alzheimer's disease result in alternative processing of amyloid β-protein precursor. J. Biol. Chem. 269, 17741-17748.
33. Hardy J. (1997a) Amyloid, the presenilins and Alzheimer's disease. Trends Neurosci. 20, 154-159.
34. Hardy J. (1997b) Comment. Trends Neurosci. 20, 559.
35. Hardy J. A. and Higgins G. A. (1992) Alzheimer's disease: the amyloid cascade hypothesis. Science 256, 184-185.
36. Hensley K., Carney J. M., Mattson M. P., Aksenova M., Harris M., Wu J. F., Floyd R. A., and Butterfield D. A. (1994) A model for beta-amyloid aggregation and neurotoxicity based on free radical generation by the peptide: relevance to Alzheimer disease. Proc. Natl. Acad. Sci. USA 91, 3270-3274.
37. Holcomb L., Gordon M. N., McGowan E., Benkovic S., Jantzen P., Wright K., Saad I., Mueller R., Morgan D., Sanders S., Zehr C., O'Campo K., Hardy J., Prada C. M., Eckman C., Younkin S., Hsiao K., and Duff K. (1998) Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nat. Med. 4, 97-100.
38. Howlett D. R., Jennings K. H., Lee D. C., Clark M. S. G., Brown F., Wetzel R., Wood S. J., Camilleri P., and Roberts G. W. (1995) Aggregation state and neurotoxic properties of Alzheimer beta-amyloid peptide. Neurodegeneration 4, 23-32.
39. Hsiao K. (1998) Transgenic mice expressing Alzheimer amyloid precursor proteins. Exp. Gerontol. 33, 883-889.
40. Hsiao K., Chapman P., Nilsen S., Eckman C., Harigaya Y., Younkin S., Yang F., and Cole G. (1996) Correlative memory deficits, Aβ elevation, and amyloid plaques in transgenic mice. Science 274, 99-102.
41. Irizarry M. C., McNamara M., Fedorchak K., Hsiao K., and Hyman B. T. (1997) APP(SW) transgenic mice develop age-related Aβ deposits and neuropil abnormalities, but no neuronal loss in CA1. J. Neuropathol. Exp. Neurol. 56, 965-973.
42. Jarrett J. T. and Lansbury P. T. (1993) Seeding "one-dimensional crystallization" of amyloid: a pathogenic mechanism in Alzheimer's disease and scrapie? Cell 73, 1055-1058.
43. Johnston J., O'Neill C., Lannfelt L., Winblad B., and Cowburn R. F. (1994) The significance of the Swedish APP670/671 mutation for the development of Alzheimer's disease amyloidosis. Neurochem. Int. 25, 73-80.
44. Kang J., Lemaire H. G., Unterbeck A., Salbaum J. M., Masters C. L., Grzeschik K. H., Multhaup G., Beyreuther K., and Müller-Hill B. (1987) The precursor of Alzheimer's disease A4 protein resembles a cell surface receptor. Nature 325, 733-736.
45. Kisilevsky R. (1994) Amyloidosis, in Pathology (Rubin E. and Farber J. L., eds), pp. 1163-1174. J. B. Lippincott, Philadelphia.
46. Kowall N. W., Beal M. F., Busciglio J., Duffy L. K., and Yankner B. A. (1991) An in vivo model for the neurodegenerative effects of β amyloid and protection by substance P. Proc. Natl. Acad. Sci. USA 88, 7247-7251.
47. Kuo Y. M., Emmerling M. R., Vigo-Pelfrey V., Kasunic T. C., Kirkpatrick J. B., Murdoch G. H., Ball M. J., and Roher A. E. (1996) Water-soluble Aβ (N-40, N-42) oligomers in normal and Alzheimer disease brains. J. Biol. Chem. 271, 4077-4081.
48. Kwok J. B. J., Li Q. X., Hallupp M., Milward L., Whyte S., and Schofield P. R. (1998) Novel familial early-onset Alzheimer's disease mutation (Leu723Pro) in amyloid precursor protein (APP) gene increases production of 42(43) amino-acid isoform of amyloid-beta peptide. Neurobiol. Aging 19 (Suppl. 4), S91.
49. LaDu M. J., Falduto M. T., Manelli A. M., Reardon C. A., Getz G. S., and Frail D. E. (1994) Isoform-specific binding of apolipoprotein E to β-amyloid. J. Biol. Chem. 269, 23403-23406.
50. 1-42 are potent central nervous system neurotoxins. Proc. Natl. Acad. Sci. USA 95, 6448-6453.
51. Lee S. J., Liyanage U., Bickel P. E., Xia W. M., Lansbury P. T., and Kosik K. S. (1998) A detergent-insoluble membrane compartment contains Aβ in vivo. Nat. Med. 4, 730-734.
52. Lee V. M. Y., Balin B. J., Otvos L., and Trojanowski J. Q. (1991) A68: a major subunit of paired helical filaments and derivatized forms of normal tau. Science 251, 675-678.
53. Ma J., Yee A., Brewer H. B. Jr., Das S., and Potter H. (1994) Amyloid-associated protein α(1)-antichymotrypsin and apolipoprotein E promote assembly of Alzheimer β-protein into filaments. Nature 372, 92-94.
54. Mahley R. W. (1988) Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science 240, 622-630.
55. 2+ homeostasis and cell death. J. Neurosci. 15, 6239-6249.
56. Masliah E., Sisk A., Mallory M., Mucke L., Schenk D., and Games D. (1996) Comparison of neurodegenerative pathology in transgenic mice overexpressing V717F β-amyloid precursor protein. J. Neurosci. 16, 5795-5811.
57. Masters C. L. and Beyreuther K. (1993) Strategic thoughts on the Alzheimer's disease amyloid protein precursor: the way forward, in Amyloid Protein Precursor in Development, Aging and Alzheimer's Disease (Masters C. L., Beyreuther K., Trillet M., and Christen Y., eds), pp. 1-8. Springer-Verlag, Berlin.
58. Masters C. L., Simms G., Weinman N. A., Multhaup G., McDonald B. L., and Beyreuther K. (1985) Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc. Natl. Acad. Sci. USA 82, 4245-4249.
59. Mattson M. P., Cheng B., Davis D., Bryant K., Lieberburg I., and Rydel R. E. (1992) β-Amyloid peptides destabilize calcium homeostasis and render human cortical neurons vulnerable to excitotoxicity. J. Neurosci. 12, 376-389.
60. 2+ homeostasis in Alzheimer's disease. Trends Neurosci. 16, 409-414.
61. Mattson M. P., Tomaselli K. J., and Rydel R. E. (1993b) Calcium-destabilizing and neurodegenerative effects of aggregated beta-amyloid peptide are attenuated by basic FGF. Brain Res. 621, 35-49.
62. Mehta N. D., Refolo L. M., Eckman C., Sanders S., Yager D., Perez-Tur J., Younkin S., Duff K., Hardy J., and Hutton M. (1998) Increased Aβ42(43) from cell lines expressing presenilin 1 mutations. Ann. Neurol. 43, 256-258.
63. Murrell J., Farlow M., Ghetti B., and Benson M. D. (1991) A mutation in the amyloid precursor protein associated with hereditary Alzheimer's disease. Science 254, 97-99.
64. Naruse S., Igarashi S., Kobayashi J., Aoki K., Inuzuka T., Kaneko K., Shimizu T., Iihara K., Kojima T., Miyatake T., and Tsuji S. (1991) Mis-sense mutation Val-→Ile in exon 17 of amyloid precursor protein gene in Japanese familial Alzheimer's disease. Lancet 337, 978-979.
65. Pappolla M. A., Chyan Y. J., Omar R. A., Hsiao K., Perry G., Smith M. A., and Bozner P. (1998) Evidence of oxidative stress and in vivo neurotoxicity of β-amyloid in a transgenic mouse model of Alzheimer's disease - a chronic oxidative paradigm for testing antioxidant therapies in vivo. Am. J. Pathol. 152, 871-877.
66. Pike C. J., Walenzcewicz A. J., Glabe C. G., and Cotman C. W. (1991) In vitro aging of β-amyloid protein causes peptide aggregation and neurotoxicity. Brain Res. 563, 311-314.
67. Podlisny M. B., Walsh D. M., Amarante P., Ostaszewski B. L., Stimson E. R., Maggio J. E., Teplow D. B., and Selkoe D. J. (1998) Oligomerization of endogenous and synthetic amyloid beta-protein at nanomolar levels in cell culture and stabilization of monomer by Congo Red. Biochemistry 37, 3602-3611.
68. Price J. L., Davis P. B., Morris J. C., and White D. C. (1991) The distribution of tangles, plaques and related immunohistochemical markers in healthy aging and Alzheimer's disease. Neurobiol. Aging 12, 295-312.
69. Probst A., Langui D., and Ulrich J. (1991) Alzheimer's disease: a description of the structural lesions. Brain Pathol. 1, 229-239.
70. Roher A. E., Chaney M. O., Kuo Y. M., Webster S. D., Stine W. B., Haverkamp L. J., Woods A. S., Cotter R. J., Tuohy J. M., Krafft G. A., Bonnell B. S., and Emmerling M. R. (1996) Morphology and toxicity of Aβ-(1-42) dimer derived from neuritic and vascular amyloid deposits of Alzheimer's disease. J. Biol. Chem. 271, 20631-20635.
71. Roses A. D. (1994) Apolipoprotein E affects the rate of Alzheimer's disease expression: β-amyloid burden is a secondary consequence dependent on APOE genotype and duration of disease. J. Neuropathol. Exp. Neurol. 53, 429-437.
72. Samuel W., Terry R. D., DeTeresa R., Butters N., and Masliah E. (1994) Clinical correlates of cortical and nucleus basalis pathology in Alzheimer dementia. Arch. Neurol. 51, 772-778.
73. Scheuner D., Eckman C., Jensen M., Song X., Citron M., Suzuki N., Bird T. D., Hardy J., Hutton M., Kukull W., Larson E., Levy-Lahad E., Viitanen M., Peskind E., Poorkaj P., Schellenberg G., Tanzi R., Wasco W., Lannfelt L., Selkoe D., and Younkin S. (1996) Secreted amyloid β-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat. Med. 2, 864-870.
74. Schmechel D. E., Saunders A. M., Strittmatter W. J., Crain B. J., Hulette C. M., Joo S. H., Pericak-Vance M. A., Goldgaber D., and Roses A. D. (1993) Increased amyloid β-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. Proc. Natl. Acad. Sci. USA 90, 9649-9653.
75. Selkoe D. J. (1997) Alzheimer's disease: genotypes, phenotype and treatments. Science 275, 630-631.
76. Skovronsky D. M., Doms R. W., and Lee V. M. Y. (1998) Detection of a novel intraneuronal pool of insoluble amyloid β protein that accumulates with time in culture. J. Cell Biol. 141, 1031-1039.
77. Small D. H. (1998) The role of the amyloid protein precursor (APP) in Alzheimer's disease: does the normal function of APP explain the topography of neurodegeneration? Neurochem. Res. 23, 795-806.
78. Small D. H., Mok S. S., Williamson T., and Nurcombe V. (1996) The role of proteoglycans in neural development, regeneration and the aging brain. J. Neurochem. 67, 889-899.
79. Smith M. A., Hirai K., Hsiao K., Pappolla M. A., Harris P. L. R., Siedlak S. L., Tabaton M., and Perry G. (1998) Amyloid-β deposition in Alzheimer transgenic mice is associated with oxidative stress. J. Neurochem. 70, 2212-2215.
80. Song D.-K., Won M.-H., Jung J. S., Lee J.-C, Kang T.-C., Suh H.-W., Huh S.-O., Paek S.-H., Kim Y.-H., Kim S.-H., and Suh Y.-H. (1998) Behavioral and neuropathologic changes induced by central injection of carboxyl-terminal fragment of β-amyloid precursor protein in mice. J. Neurochem. 71, 875-878.
81. Spillantini M. G. and Goedert M. (1998) Tau protein pathology in neurodegenerative diseases. Trends Neurosci. 21, 428-433.
82. Strittmatter W. J., Saunders A. M., Schmechel D., Pericak-Vance M., Enghild J., Salvesen G. S., and Roses A. D. (1993a) Apolipopro-tein E: high-avidity binding to β-amyloid and increased frequency of type 4 allele in late-onset Alzheimer disease. Proc. Natl. Acad. Sci. USA 90, 1977-1981.
83. Strittmatter W. J., Weisgraber K. H., Huang D. Y., Dong L. M., Salvesen G. S., Pericak-Vance M., Schmechel D., Saunders A. M., Goldgaber D., and Roses A. D. (1993b) Binding of human apolipoprotein E to synthetic amyloid βpeptide: isoform-specific effects and implications for late-onset Alzheimer disease. Proc. Natl. Acad Sci. USA 90, 8098-8102.
84. Sturchler-Pierrat C., Abramowski D., Duke M., Wiederhold K. H., Mistl C., Rothacher S., Ledermann B., Burki K., Frey P., Paganetti P. A., Waridel C., Calhoun M. E., Jucker M., Probst A., Staufenbiel M., and Sommer B. (1997) Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proc. Natl. Acad. Sci. USA 94, 13287-13292.
85. Suzuki N., Cheung T. T., Cai X. D., Odaka A., Otvos L., Eckman C., Golde T. E., and Younkin S. G. (1994) An increased percentage of long amyloid βprotein secreted by familial amyloid βprotein precursor (βAPP717) mutants. Science 264, 1336-1340.
86. Tanzi R. and Hyman B. T. (1991) Alzheimer's mutation. Nature 350, 564.
87. Teller J. K., Russo C., Debusk L. M., Angelini G., Zaccheo D., Dagnabricarelli F., Scartezzini P., Bertolini S., Mann D. M. A., Tabaton M., and Gambetti P. (1996) Presence of soluble amyloid beta-peptide precedes amyloid plaque formation in Down's syndrome. Nat. Med. 2, 93-95.
88. Terry R. D. (1963) The fine structure of neurofibrillary tangles in Alzheimer's disease. J. Neuropathol. Exp. Neurol. 22, 629-642.
89. Terry R. D., Masliah E., Salmon D. P., Butters N., DeTeresa R., Hill R., Hansen L. A., and Katzman R. (1991) Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann. Neurol. 30, 572-580.
90. 2+ channels: a possible involvement of free radicals. J. Neurochem. 68, 265-271.
91. Yan S. D., Chen X., Fu J., Chen M., Zhu H. J., Roher A., Slattery T., Zhao L., Nagashima M., Morser J., Migheli A., Nawroth P., Stern D., and Schmidt A. M. (1996) RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease. Nature 382, 685-691.
92. Yan S. D., Fu J., Soto C., Chen X., Zhu H. J., Al Mohanna F., Collison K., Zhu A. P., Stern E., Saido T., Tohyama M., Ogawa S., Roher A., and Stern D. (1997) An intracellular protein that binds amyloid-beta peptide and mediates neurotoxicity in Alzheimer's disease. Nature 389, 689-695.
93. Yang D.-S., Smith J. D., Zhou Z., Gandy S. E., and Martins R. N. (1997) Characterization of the binding of amyloid-β peptide to cell culture-derived apolipoprotein E2, E3, and E4 isoforms and to isoforms from human plasma. J. Neurochem. 68, 721-725.
94. Yankner B. A., Dawes L. R., Fisher S., Villa-Komaroff L., Oster-Granite M. L., and Neve R. L. (1989) Neurotoxicity of a fragment of the amyloid precursor associated with Alzheimer's disease. Science 245, 417-420.
95. Yoshikai S., Sasaki H., Doh-ura K., Furuya H., and Sakaki Y. (1990) Genomic organization of the human amyloid beta-protein precursor gene. Gene 87, 257-263.
96. Zhou Z., Smith J. D., Greengard P., and Gandy S. (1996) Alzheimer amyloid-β peptide forms denaturant-resistant complex with type ∈3 but not with type ∈4 isoform of native apolipoprotein E. Mol. Med. 2, 175-180.